Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)

Author:

Spinou AriettaORCID,Hererro-Cortina Beatriz,Aliberti StefanoORCID,Goeminne Pieter C.,Polverino Eva,Dimakou Katerina,Haworth Charles S.,Loebinger Michael R.,De Soyza AnthonyORCID,Vendrell Montserrat,Burgel Pierre RegisORCID,McDonnell MelissaORCID,Sutharsan Sivagurunathan,Škrgat Sabina,Maiz-Carro Luiz,Sibila Oriol,Stolz Daiana,Kauppi Paula,Bossios ApostolosORCID,Hill Adam T.,Clifton Ian,Crichton Megan L.,Walker Paul,Menendez Rosario,Borekci Sermin,Obradovic Dusanka,Nowinski Adam,Amorim Adelina,Torres AntoniORCID,Lorent NatalieORCID,Welte TobiasORCID,Blasi Francesco,Jankovic Makek MatejaORCID,Shteinberg MichalORCID,Boersma Wim,Elborn J. Stuart,Chalmers James D.,Ringshausen Felix C.ORCID

Abstract

BackgroundInternational guidelines recommend airway clearance management as one of the important pillars of bronchiectasis treatment. However, the extent to which airway clearance is used for people with bronchiectasis in Europe is unclear. The aim of the study was to identify the use of airway clearance management in patients with bronchiectasis across different countries and factors influencing airway clearance use.MethodsThis was a prospective observational study using data from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) Registry between January 2015 and April 2022. Prespecified options for airway clearance management were recorded, including airway clearance techniques, devices and use of mucoactive drugs.Results16 723 people with bronchiectasis from 28 countries were included in the study. The mean age was 67 years (interquartile range 57–74 years, range 18–100 years) and 61% were female. 72% of the participants reported daily sputum expectoration and 52% (95% CI 51–53%) of all participants reported using regular airway clearance management. Active cycle of breathing technique was used by 28% of the participants and airway clearance devices by 16% of participants. The frequency of airway clearance management and techniques used varied significantly between different countries. Participants who used airway clearance management had greater disease severity and worse symptoms, including a higher daily sputum volume, compared to those who did not use it regularly. Mucoactive drugs were also more likely to be used in participants with more severe disease. Access to specialist respiratory physiotherapy was low throughout Europe, but particularly low in Eastern Europe.ConclusionsOnly a half of people with bronchiectasis in Europe use airway clearance management. Use of and access to devices, mucoactive drugs and specialist chest physiotherapy appears to be limited in many European countries.

Funder

European Respiratory Society

Publisher

European Respiratory Society (ERS)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3